Optomed Plc
Tessa Sipilä has a range of work experience, starting with their current position as the Marketing & Business Development Lead at Optomed Plc. Prior to this, they worked as a Business Development Manager at the same company. Before joining Optomed, Tessa worked as a Territory Manager at Abbott for three years. Tessa also has experience at Dual Laser Ltd. Oy, where they started as a Product Specialist and later became a Product Manager. In this role, they were responsible for sales, budgeting, product training, marketing activities, and customer relationship management. Tessa's earlier experience includes working as a Research Scientist at the University of Helsinki, where they studied the genetic background of anxiety disorders, and as a Master's student, where they focused on circadian clock-related genes as candidate genes for anxiety disorders.
Tessa Sipilä holds a Master's Degree in Cell/Cellular and Molecular Biology from the University of Jyväskylä, which they obtained from 2003 to 2008. In 2007, they briefly studied Biomedical studies: genetics and immunology at the University of Aberdeen. In 2011, they took Kasvatustieteiden perusopinnot (yleinen ja aikuiskasvatustiede) at the University of Helsinki. Currently, they are pursuing a Teacher's pedagogical qualification at the Haaga-Helia School of Vocational Teacher Education, expected to be completed in 2022.
This person is not in any offices
Optomed Plc
Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company’s products are sold via various sales channels in over 60 countries globally. The company has an extensive portfolio of over 50 international patents protecting the technology. The products have medical approvals in all key markets, including CE (Europe) and FDA (USA), and CFDA (China).